Tetrahydroquinoline sulfonamides as vasopressin 1b receptor anatgonists

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 21, 2009, Pages 6018-6022

  Scott, Jack D ^a   Miller, Michael W ^a   Li, Sarah W ^a   Lin, Sue Ing ^a   Vaccaro, Henry A ^a   Hong, Liwu ^a   Mullins, Deborra E ^a   Guzzi, Mario ^a   Weinstein, Jay ^a   Hodgson, Robert A ^a   Varty, Geoffrey B ^a   Stamford, Andrew W ^a   Chan, Tin Yau ^a   McKittrick, Brian A ^a   Greenlee, William J ^a   Priestley, Tony ^a   Parker, Eric M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anxiety; Depression; V1b antagonist; V1b receptor; Vasopressin

Indexed keywords

AMINOPIPERIDINE; PIPERIDINE DERIVATIVE; SULFONAMIDE; TETRAHYDROQUINOLINE SULFONAMIDE; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1B RECEPTOR;

ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG SCREENING; DRUG SELECTIVITY; RECEPTOR AFFINITY; RECEPTOR BINDING;

ANIMALS; ANTIDIURETIC AGENTS; HUMANS; QUINOLINES; RATS; RECEPTORS, OXYTOCIN; RECEPTORS, VASOPRESSIN; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

RATTUS;

EID: 71749109407     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.09.050     Document Type: Article

References (15)

1. Aguilera G., and Rabadan-Diehl C. Regul. Pept. 96 (2000) 23
2. Gillies G.E., Linton E.A., and Lowry P.J. Nature 299 (1982) 355
3. Tanoue A., Ito S., Honda K., Oshikawa S., Kitagawa Y., Koshimizu T., Mori T., and Tsujimoto G. J. Clin. Invest. 113 (2004) 302
4. For a review of SSR149415 see:. Serradeil-Le Gal C., Wagnon J., Tonnerre B., Roux R., Garcia G., Griebel G., and Aulombard A. CNS Drug Rev. 11 (2005) 53
5. Oxytocin is a nonapeptidic hormone with similar structure to vasopressin.
6. Hodgson R.A., Higgins G.A., Guthrie D.H., Lu S.X., Pond A.J., Mullins D.E., Guzzi M.F., Parker E.M., and Varty G.B. Pharmacol. Biochem. Behav. 86 (2007) 431
7. Griffante C., Green A., Curcuruto O., Haslam C.P., Dickinson B.A., and Arban R. Br. J. Pharmacol. 146 (2005) 744
8. Craighead M., Milne R., Campbell-Wan L., Watson L., Presland J., Thomson F.J., Marston H.M., and MacSweeney C.P. Prog. Brain Res. 170 (2008) 527
9. Spiga F., Harrison L.R., Wood S., Knight D.M., MacSweeney C.P., Thomson F., Craighead M., and Lightman S.L. J. Endocrinol. 200 (2009) 273
10. Spiga F., Harrison L.R., MacSweeney C.P., Thomson F.J., Craighead M., and Lightman S.L. J. Endocrinol. 200 (2009) 285
11. Asberom T., Bara T.A., Clader J.W., Greenlee W.J., Guzik H.S., Josien H.B., Li W., Parker E.M., Pissarnitski D.A., Song L., Zhang L., and Zhao Z. Bioorg. Med. Chem. Lett. 17 (2007) 205
12. The human and rat V1b receptors have 83% homology:. Lolait S.J., O'Carroll A.-M., Mahan L.C., Felder C.C., Button D.C., Young III W.S., Mezey E., and Brownstein M.J. Proc. Natl. Acad. Sci. 92 (1995) 6783
13. i was determined using the Cheng-Prusoff equation.
14. Brouwer A.J., Monnee M.C.F., and Liskamp R.M.J. Synthesis 11 (2000) 1579
15. Analytical chiral HPLC conditions: Chiralpak AS column, 70:30 hexanes/EtOH, flow 1 mL/min, UV detector: 254 nm. Retention time enantiomer (A) 10 min, enantiomer (B) 13.6 min. Each enantiomer from preparative scale separation was determined to be ≥98% ee via analytical HPLC.